Suite 514 100 Victoria Parade
East Melbourne, VIC 3002
Tel: 03 9654 8906
Fax 03 9654 8909
Private Hospital Accreditations
St.Vincent's Private Hospital
Victoria Parade, East Melbourne.
Epworth Richmond. Bridge Road, Richmond.
MBBS(Hons) SpecCertOC FRACP FRCPA MD
- Consultant Haematologist
Dr Hang Quach is a Consultant clinical and laboratory Haematologist at St.Vincent's Hospital, Melbourne. She graduated from University of Melbourne and completed her specialist training in internal medicine, clinical and laboratory haematology through the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia. She subsequently completed a higher degree of Doctor of Medicine (MD) with the University of Melbourne in 2010, after 3 years of research at the Peter MacCallum Cancer Centre that focused on the immunology and novel therapeutics for multiple myeloma.
Dr Quach's career in haematology is accentuated by her strong involvement in both clinical and laboratory research, that has resulted in many publications in high impact medical journals. As a member of the Australian Medical Scientific Advisory Group for Myeloma (MSAG), Dr Quach has led the development of an Australian guideline for the treatment of Mutliple Myeloma for physicians. She has also contributed extensively to educational materials about multiple myeloma and lymphoma for patients and families through the Australian Myeloma Foundation and the Australian Leukaemia Foundation.
Dr Quach's main area of expertise is malignant haematological disorders including multiple myeloma, lymphoma, myelodysplastic and myeloproliferative diseases. She will also consult on non-malignant haematological disorders including clotting and bleeding disorders. Dr Quach is well known for her dedication and willingness to go to great lengths to achieve optimal outcome for her patients.
- Quach H, Davis S., Radiotherapy in orbital lymphoma :optimising the backbone to build upon. Leuk Lymphoma. 2012 Sep 11. [Epub ahead of print]
- Quach H, Kalff A, Spencer A,.Lenalidomide in multiple myeloma: Current status and future potential. Am J Hematol. 2012 Apr 26. doi: 10.1002/ajh.23234. [Epub ahead of print]
- Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ, Neeson P, Ritchie DS., The Immunostimulatory effect of lenalidomide on NK cell function is profoundly inhibited by concurrent dexamethasone therapy [original study]. Blood 2011; 117(5):1605-13
- Quach H, Prince HM, Spencer A., Treatment Of Multiple Myeloma In The Elderly: Are We Making Progress? [review article]. Expert Rev Hematol 2011; 4 (3):301-305.
- Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM., Mechanism of Action of Immunomodulatory Drugs (IMiDs) in Multiple Myeloma [Review]. Leukemia. 2010;24(1):22-32.
- Ritchie DS, Quach H, Fielding K, Neeson P., Drug-Mediated and Cellular Immunotherapy in Multiple Myeloma. Immunotherapy Immunotherapy 2010 [Review]; 2(2):243-255.
- Quach H, Mileshkin L, Seymour JF, Milner A, Ritchie D, Harrison S, Westerman D, Prince HM., Predicting durable remissions following thalidomide therapy for relapsed myeloma [original study]. Leuk Lymphoma 2009; 50 (2): 223-229.
- Quach H, Horvath N, Cannell P, Mikhael JR, Butcher BE, Prince HM., Safety and efficacy results from an international Expanded Access Program to Bortezomib for patients with relapsed and / or refractory multiple myeloma: a subset analysis of the Australian & New Zealand data of 111 patients. [orignal study] Int Med J 2009; 39(5): 290-5
- Quach H, Prince HM, Mileshkin L., Treatment Strategies in Elderly Patients with Multiple Myeloma: Current Status [Review]. Drugs Aging 2007;24 (10):829-50.
- Medical Scientific Advisory Group Australia (MSAG)
- Haematology Society of Australia and New Zealand (HSANZ)
- Australasian Leukaemia and Lymphoma Group (ALLG)